ロード中...
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR designs, manufacturing processes, and study populations, among other variables, have been tested and reported in over 10 clinic...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3999751/ https://ncbi.nlm.nih.gov/pubmed/24578504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-492231 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|